CDI Breakthroughs Lead to New Drug Development Deal for Deadly NTM Bacteria
The CDI’s top NTM scientists, Véronique Dartois, Ph.D., and Thomas Dick, Ph.D., have developed new compounds which are now subject of a new collaboration and license agreement with the Switzerland-based and publicly listed BioVersys AG. As announced on March 31, the two parties will jointly profile and develop rifamycin candidates identified by HMH.